

ANALYSIS OF OFF-LABEL USE OF LEVOSIMENDAN IN PAEDIATRICS

J. Mateo Carmona, O. García Molina, V. Arocas Casañ, M.A. Fernandez De Palencia Espinosa, M. Valderrey Pulido, S. Vicente Sanchez, A. Tomas Luiz, M.M. Ruiz Jimenez, P. De La Cruz Murie, M. Galindo Rueda.
Servicio Farmacia Hospital CU Virgen de la Arrixaca

Objectives

To analyse the use of levosimendan for off label use in children for congenital heart disease and the survival rate.

Material and methods

- ❑ An observational retrospective descriptive study from October 2009 to April 2015
- ❑ The following data was collected: age, diagnosis, dosage, analytical variables pre- and post- levosimendan administration and the survival rate.

Results

- ❑ Patients
 - 23 patients (between one day and 1.4 years)
 - median age of 90 days [13.5-195.1].
- ❑ Surgery
 - 20 children with extracorporeal circulation.
- ❑ No surgery
 - 2 children had heart failure refractory to vasoactive drugs
 - 1 patient with dilated cardiomyopathy.
- ❑ 4 of the 23 children who had been treated with levosimendan died (17.4%).

	Pre-levosimendan	Post-levosimendan	p
Lactate (mmol/L)	3,7±4,1	2,1 ±2,9	0,092
Hemoglobin (g/dL)	12,7 ±2,5	11,4 ±2,1	0,072
Potassium (mEq/L)	4,5 ±0,7	3,9 ±0,5	0,054
Creatinine (mg/dL)	0,4 ±0,2	0,6 ±0,4	0,056

Conclusions

- Levosimendan is used off-label in paediatric cardiac surgery.
- There were improvements in the analytical variables but no statistically
- In our data, survival rates was similar to that reported in other studies published.